357 related articles for article (PubMed ID: 19640210)
21. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens G; Jackson R; Lewiecki EM
Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
[TBL] [Abstract][Full Text] [Related]
22. Predictors of patients' perceived need for medication to prevent fracture.
Schousboe JT; Davison ML; Dowd B; Thiede Call K; Johnson P; Kane RL
Med Care; 2011 Mar; 49(3):273-80. PubMed ID: 21224740
[TBL] [Abstract][Full Text] [Related]
23. Osteoporosis management: translating research into optimal fracture protection II.
Singer AJ; Boonen S
Curr Med Res Opin; 2008 Jun; 24(6):1789-96. PubMed ID: 18559165
[TBL] [Abstract][Full Text] [Related]
24. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
Siris ES; Selby PL; Saag KG; Borgström F; Herings RM; Silverman SL
Am J Med; 2009 Feb; 122(2 Suppl):S3-13. PubMed ID: 19187810
[TBL] [Abstract][Full Text] [Related]
25. [Prophylaxis of glucocorticoid-induced osteoporosis].
Tanaka Y
Clin Calcium; 2006 Nov; 16(11):1858-65. PubMed ID: 17079853
[TBL] [Abstract][Full Text] [Related]
26. Treatment of osteoporosis: all the questions we still cannot answer.
Laroche M
Am J Med; 2008 Sep; 121(9):744-7. PubMed ID: 18724959
[TBL] [Abstract][Full Text] [Related]
27. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
28. [Adherence to treatment in osteoporosis influence on efficiency].
Reginster JY; Rabenda V
Rev Med Suisse; 2005 Oct; 1(35):2278-81. PubMed ID: 16268451
[TBL] [Abstract][Full Text] [Related]
29. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
[TBL] [Abstract][Full Text] [Related]
30. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
[TBL] [Abstract][Full Text] [Related]
31. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
32. [Vitamin K2 treatment for osteoporosis: what is the evidence today?].
Ishida Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():409-14. PubMed ID: 18161141
[No Abstract] [Full Text] [Related]
33. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence.
Sampalis JS; Adachi JD; Rampakakis E; Vaillancourt J; Karellis A; Kindundu C
J Bone Miner Res; 2012 Jan; 27(1):202-10. PubMed ID: 21976304
[TBL] [Abstract][Full Text] [Related]
34. Clinical and therapeutic aspects of osteoporosis.
Compston J
Eur J Radiol; 2009 Sep; 71(3):388-91. PubMed ID: 19660883
[TBL] [Abstract][Full Text] [Related]
35. Oral bisphosphonate compliance and persistence: a matter of choice?
Silverman SL; Schousboe JT; Gold DT
Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
[TBL] [Abstract][Full Text] [Related]
36. Treatments for osteoporosis in people with a disability.
Smith EM
PM R; 2011 Feb; 3(2):143-52. PubMed ID: 21333953
[TBL] [Abstract][Full Text] [Related]
37. Adherence to bisphosphonate treatment by elderly women.
Berecki-Gisolf J; Hockey R; Dobson A
Menopause; 2008; 15(5):984-90. PubMed ID: 18520695
[TBL] [Abstract][Full Text] [Related]
38. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
39. Are beta-blockers useful in the prevention of osteoporotic fractures?
Pérez-Castrillón JL; De Luis DA; Duenas-Laita A
Eur Rev Med Pharmacol Sci; 2009; 13(3):157-62. PubMed ID: 19673165
[TBL] [Abstract][Full Text] [Related]
40. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
Horning JA; Czajka J; Uhl RL
Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
